MS: Busting the Myths
July 26, 2022 | Life with MS, Progressive, Research
Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC […]
June 29, 2022 | Advocacy, Media
Listen to MSNZ President, Neil Woodhams talk with RNZ presenters on the afternoon show ‘The Panel’. Hear him discuss the impacts Pharmac’s revised criteria for people with MS accessing medication earlier than ever before will have on people with MS […]
June 16, 2022 | Advocacy, Life with MS, Treatments
Multiple Sclerosis NZ is pleased to see the announcement this week from Pharmac to provide access to funded MS treatments earlier than ever before. The new criteria will no longer require those clinically diagnosed with MS to wait for […]
May 30, 2022 | Advocacy, Life with MS, Treatments
We are excited to announce that following 7 years of relentless advocacy by Multiple Sclerosis NZ (MSNZ), Pharmac have opened the consultation process to increase earlier access to treatments for relapsing remitting MS. We now need YOUR HELP to get […]
May 23, 2022 | Media, Treatments
Media article: 19 May 2022 Pharmac welcomes the $191 million increase to its pharmaceutical budget over the next two years. It is already working its way through the medicines options for investment (OFI) list, looking at what agreements it can […]